Clinical Genomic Database for Asian-Prevalent Cancers

Request Number N225787
Author Pfizer
Need details

Pfizer's Worldwide R&D organization wishes to pursue potential research collaborations with Asia’s leading academic hospitals, clinical research groups and biotechnology companies with clinical genomic databases related to cancers that are prevalent in Asian population such as gastric, liver, esophageal and lung cancers.


Asian prevalent cancers such as gastric and liver cancers present a major unmet medical need but the molecular bases of these lethal diseases remains poorly understood.


Advances in NGS technologies are enabling wide-spread use of genomic profiling in the clinical setting to elucidate molecular changes associated with tumors. Well-defined molecular biomarkers such as oncogenic mutations are critical for selecting pre-clinical models and stratifying patient populations for testing of oncology drug candidates. Oncogenic mutations such as ERBB2 amplification may occur in multiple cancers but usually affect only a minority of patients in a single indication. It is of key interest in drug discovery to identify the occurrences and estimate the prevalence of mutations across multiple cancer indications. This information may help design clinical studies and recruit subsets of patients affected by the mutation into the studies. Moreover, cell lines or xenograft models can be derived from mutated primary tumors to perform target validation and drug testing experiments.


NGS profiling of large numbers of cancer patients makes it possible to assemble sufficiently powered cohorts and identify rare mutations. Finally, linking molecular profiles with drug response data can help to pinpoint molecular changes underlying drug response and resistance, thus enabling the development of new drugs or drug combinations.


Key Success Criteria

Pfizer’s Oncology Research Unit is interested in partnering with groups that have electronic databases of genetic alterations including single nucleotide substitutions, insertions, deletions, copy number changes and chromosomal rearrangements based on Next-Generation Sequencing (NGS) profiling of tumors from cancer patients.


These genetic profiles may be derived from targeted sequencing of known cancer genes or whole exome/genome sequencing. Pfizer is interested in data on many cancer types that have a higher prevalence in Asian populations including gastric, liver, esophageal and lung cancers.


Successful databases require the following specifications:

  1. Database should be organized by international standards (English, HUGO gene symbols etc.) with the data regularly curated, updated and available to Pfizer through transfer of complete data sets
  2. Informed consent should be in place to allow broad research use of tissue specimens and derived genetic data
  3. Tumor molecular profiles need to have annotations on tumor diagnosis, histology and whenever applicable, drug response and survival data
  4. It is preferable that tumor molecular profiles are linked to tissue specimens stored in a biobank in conditions amenable for creating cell cultures or xenograft. Tissues should be available for RNA profiling, IHC or proteomics analysis
Possible Approaches
 Preferred Collaboration Type:

Pfizer seeks to establish strong collaborative relationships with leading academic hospitals, universities, research institutes or biotech companies in Asia who can provide access to databases of genetic information obtained from profiling tumors from cohorts of cancer patients.


Pfizer may perform integrative analysis of the genetic profiles and collaborate in the publication of the results.


Pfizer may provide genetic profiling of tissues using experimental assays on selective cases and may provide compounds for use in research studies where applicable.


IP Requirements:

Pfizer should have the freedom to develop drugs or diagnostics based on information derived from the data.


Approaches not of interest

The following approaches are not of interest:

  1. Retrospective studies focused on discovery of novel cancer genes
  2. Approaches that require Pfizer resources to initiate tumor collection or perform NGS profiling



Preferred Collaboration types
  • To Be Negotiated
Items to be submitted

Your response should be in the form of a concise NON-CONFIDENTIAL abstract/executive summary. The proposal should briefly describe the technical approach and provide information on technology performance, background and description of the responding team and their related experience. To Respond, please use the Respond button located on the Need page. Please note that only non-confidential information can be accepted.  By submitting a response you represent that the response does not contain and will not be deemed to contain any confidential information of any kind whatsoever. By submitting a response, you also acknowledge and confirm that you have consulted with your Technology Transfer Office, Business Development Office or any other required group and that you have their approval to submit the response.  All Personal Information disclosed to Pfizer within a response will be utilized in accord with principles and polices as described at  By submitting a response, you acknowledge that the Need's sponsoring organization, in its sole discretion, may select or reject a response or any portion thereof.  Your NineSights community profile should contain all required information in order to provide us with appropriate contact information for your responses. For questions about NineSights privacy and security, please feel free to post in our Community Help forums.


Point of Contact
Darren Coomber
Area of Interest
  • Medical Products & Services
Due Date
October 30, 2015
Award Amount
Creation date Document title  
September 16, 2014 Clinical Genomic Database for Asian-Prevalent Cancers.pdf